Articles tagged with Neuropathic Pain
A new clinical trial aims to test personalized brain stimulation targeting two pain-related brain networks for patients with severe, treatment-resistant central neuropathic pain. Researchers will use functional MRI to map each participant's brain and adjust stimulation settings based on individual responses.
Researchers at the University of Warwick have identified TRPM2 as a direct pain transducer that amplifies chronic pain signals. Blocking TRPM2 with a drug injected into the joint completely reversed arthritis pain in mice, providing a promising new approach to treating chronic pain more effectively.
A clinical trial found significant improvements in pain and sensation in people with treatment-resistant painful diabetic neuropathy after receiving spinal cord stimulation. The study also observed early evidence of increased density of small nerve fibers in the skin, which may indicate potential long-term benefits.
Researchers discovered that psilocybin prevents nerve injury and associated symptoms in preclinical models, protecting sensory nerve endings and preserving touch sensation. Psilocybin may offer a new intervention for preventing chemotherapy-induced peripheral neuropathy, improving patients' quality of life.
Researchers at University of Texas MD Anderson Cancer Center found that BRAF plays a key role in developing and maintaining chronic nerve pain caused by nerve damage. Using BRAF inhibitors reduced pain sensitivity in preclinical models, suggesting therapeutic potential for treating chronic nerve pain.
Researchers found that tumors can damage peripheral nerves before chemotherapy begins, leading to potential nerve damage and chronic pain. The study challenges the conventional thought that peripheral neuropathy is mostly due to chemotherapy treatment.
A study from Linköping University finds that mild COVID-19 can lead to long-term eye problems, including abnormal pupil function and strabismus, affecting daily life. Researchers developed a diagnostic model to detect these issues, which may lead to effective treatment.
Researchers found that HIV-associated protein gp120 increases nerve receptor activity, leading to increased pain sensitivity. Targeting this mechanism with drugs or genetic approaches may alleviate chronic pain associated with HIV, and could also treat other conditions.
A randomized trial found that duloxetine does not prevent painful neuropathy caused by oxaliplatin-based chemotherapy in patients with stage II or III colorectal cancer. The study suggests that duloxetine should only be used for managing existing neuropathy, not prevention.
A UCF researcher is pursuing innovative approaches to treat diabetic neuropathy without relying on pain pills and anti-depressants. Dr. Jim Nichols is investigating overlooked mechanisms in the body that may show how insulin deficiency affects sensation in limbs.
A nationwide cohort study found that semaglutide initiators had a significantly higher risk of developing nonarteritic anterior ischemic optic neuropathy compared to sodium-glucose cotransporter-2 inhibitor initiators. The absolute risk was low, but clinicians and patients should be aware of this rare but evident increased risk.
Researchers used Caenorhabditis elegans to model chemotherapy-induced neurological dysfunction and tested two compounds for improved recovery. Both sildenafil citrate and Resveramorph-3 significantly reduced seizure-like behaviors and duration, suggesting their potential as therapeutic candidates.
Scientists have discovered the molecular characteristics of human sleeping nociceptors, which are key culprits in neuropathic pain. The findings provide a new framework for understanding the emergence of neuropathic pain at the molecular level and offer potential targets for developing targeted therapies.
An updated Cochrane review of 21 clinical trials involving over 2,100 adults found no high-quality evidence that cannabis-based medicines reduce neuropathic pain more than placebo. Small improvements were reported by patients using products with both THC and CBD, but these changes were not clinically meaningful.
Researchers at MD Anderson have made significant advancements in cancer treatment, demonstrating the effectiveness of immunotherapy before and after surgery in improving lung cancer patient outcomes. Additionally, a new study shows promise in using CAR T cell therapy to treat large B-cell lymphoma, reducing relapse rates.
A study published in PNAS reveals that peripheral neuropathy can reduce macrophage immune cells' ability to clear dead cells through efferocytosis, leading to chronic pain. Restoring this process may offer a new therapeutic strategy to prevent inflammatory signaling and improve nerve repair.
A systematic review found that cannabis products with higher THC concentration provide small improvements in pain and function, but at the cost of increased risks of common adverse events. CBD-only formulations showed no benefits. Long-term research is needed to guide patients and policymakers.
Researchers at University of Cologne identify p35-mediated CDK5 hyperactivity as a central mechanism limiting nerve regeneration in diabetes. Targeted interventions using peptides restore nerve fiber growth, leading to significant motor and sensory improvements.
A cross-sectional study found that US population faces significant challenges with nervous system disorders, impacting 180.3 million people, mainly due to stroke, Alzheimer's disease, diabetic neuropathy, and migraine conditions.
Researchers have discovered a novel delivery method for CBD that effectively targets the brain's nerve cells, providing pain relief without adverse side effects. The study found that CBD-IN, a nano-micelle formulation of CBD, calms overactive nerve circuits in the areas responsible for sensing touch and pain.
New research from the University of South Australia highlights the need for personalized, multidisciplinary and empathetic care for people with Parkinson's disease. Researchers found that gaps in support lead many individuals to rely on trial-and-error approaches to manage their pain, resulting in reduced quality of life.
Researchers at MD Anderson Cancer Center identified distinct cellular microenvironments in diffuse large B-cell lymphoma tumors, providing a framework to develop therapies that engage the patient's immune system. Additionally, a study found widespread misbeliefs about the cancer risks of alcohol among Americans, highlighting the need f...
A study by Wake Forest University School of Medicine reveals that a stress response in immune cells contributes to chemotherapy-induced nerve damage. By blocking this pathway, researchers aim to develop new treatments to protect cancer patients from debilitating side effects.
A new study found that patients who continued spinal cord stimulation had similar mortality rates to the control cohort, suggesting successful pain management can avoid excess mortality. Spinal cord stimulation differs from long-term opioid therapy, which is addictive and increases mortality.
Poor blood sugar control in adolescence increases the risk of painful future complications for people with type 1 diabetes. Children diagnosed with type 1 diabetes at a young age have trouble controlling their blood sugar as teens and are more likely to develop neuropathy in adulthood.
Despite long-held assumptions, a new study reveals that the brain's somatosensory cortex holds a stable 'body map' even after limb loss. The findings have significant implications for treating phantom limb pain and restoring sensation in prosthetic limbs via brain-computer interfaces.
A new Cochrane review has found no clear evidence of benefit for ketamine in treating chronic pain conditions. The review identified an increased risk of adverse effects such as delusions and vomiting. High-quality trials are needed to determine the role of ketamine in chronic pain care.
Researchers create breakthrough imaging system that shows sensory activity in real time, enabling them to distinguish between different sensations. The technique uses a genetically encoded voltage sensor to observe electrical signals from neurons and has major implications for treating chronic pain and sensory disorders.
A large medical record study found that receiving six or more gabapentin prescriptions for low back pain significantly increases the risk of developing dementia (29% higher) and mild cognitive impairment (85% higher). Risks are particularly high among 18-64 year olds, with no age group considered safe from increased risks.
A new brain training game has shown promise in treating nerve pain, with participants experiencing significant reductions in pain and comparable relief to opioids. The PainWaive technology uses EEG headsets to track brain activity and respond in real time, providing a potential non-invasive alternative for chronic pain management.
Researchers at VCU Massey Comprehensive Cancer Center have identified AEG-1 as the active regulator of inflammation responsible for chemotherapy-induced peripheral neuropathy (CIPN). Eliminating AEG-1 using targeted therapies could provide a critical strategy for managing CIPN in cancer patients.
Nageotte nodules, previously largely ignored in research, are abundant in sensory ganglia of individuals with diabetic neuropathy and composed mainly of satellite glia and non-myelinating Schwann cells. These clusters may represent a target for drugs that protect nerves or help manage diabetic neuropathy.
Researchers at Texas Tech University Health Sciences Center have received a $1.94 million grant to study inhibitors that target peripheral neuropathic pain. The project aims to develop novel non-opioid and non-addicting therapies capable of effectively managing chronic pain.
Researchers found that female rodents experience heightened pain sensitivity due to activation of Panx1 channels releasing leptin, a hormone associated with increased pain sensitivity. This study aims to personalize treatment for patients and may explain the over-representation of women experiencing chronic pain compared to men.
A pooled data analysis found that cancer chemotherapy is linked to persistent severe peripheral nerve pain for around 4 in every 10 patients, with platinum-based drugs and taxanes associated with the highest rates of painful neuropathy. The study analyzed data from 77 eligible studies involving 10,962 participants from 28 countries.
A study led by University of Cincinnati researcher Jun-Ming Zhang investigates the link between blood vessel movement and neuropathic spontaneous pain. The research aims to understand how blood vessel movement triggers cluster firing of neurons, a key mechanism in neuropathic pain.
A study found that monochromatic infrared light combined with physical therapy significantly reduced pain and improved sleep quality in patients with peripheral diabetic neuropathy. The treatment was effective in reducing symptoms and improving functionality for patients with intense pain.
A new study found that gabapentinoids, widely used to treat neuropathic pain, increased the risk of hip fractures in older patients. The study tracked patients hospitalized for hip fractures in Australia and found a 30% increased odds of hip fracture within two months of being dispensed gabapentinoid medication.
A large multicentre cohort study has identified a specific gene linked to human pain and found that low insulin levels, depression, and alcohol use disorder are causally linked to neuropathic pain in people with diabetes. This research may lead to the development of new treatments for this devastating condition.
A team of researchers, funded by ARPA-H, aims to create an objective quantitative tool to assess pain in patients. They will use biomarkers such as stress hormones and neurotransmitters to generate a composite panel of markers that can be monitored on a portable device.
A new UBC Okanagan study emphasizes the importance of identifying and managing neuropathic pain in high-performance athletes with spinal cord injuries. The research stresses the need for sports medicine clinicians and trainers to use standardized assessment tools, including symptom-based questionnaires, to better understand and communi...
A team of researchers has developed light-activated compounds that can inhibit nerve signals locally and on demand, offering a potential treatment for neuropathic pain. The compounds, which are activated by amber-colored light, show photopharmacological activity in animal models.
A study published in JAMA Ophthalmology found an association between semaglutide and nonarteritic anterior ischemic optic neuropathy, a condition that can cause vision loss. The observational study suggests caution when prescribing semaglutide to patients at risk of this condition.
A study published in JAMA Internal Medicine found that specific exercise concomitant with chemotherapy can prevent nerve damage in many cases. The exercises reduced the incidence of CIPN (chemotherapy-induced peripheral neuropathy) by 50-70% and improved patients' perceived quality of life.
A case report describes the successful use of thoracic paravertebral blocking to manage severe chronic pain associated with post-herpetic neuralgia. The procedure, involving repeated injections of levobupivacaine and dexamethasone, resulted in significant pain subsidence and reduced medication needs.
Researchers found that five cannabis terpenes reduced chronic neuropathic pain levels comparable to morphine. The combination of terpenes and morphine enhanced pain relief without negative side effects. Terpenes offer an alternative to opioids for pain management with a better side effect profile.
Researchers at the University of Alabama at Birmingham found that blocking Tiam1 activity in spinal neurons abrogates morphine tolerance and hyperalgesia in a mouse model. Prolonged morphine treatment increased activated Tiam1 levels, leading to dendritic spine morphological changes.
A real-world study published in Pain Practice found that patients with neuropathic back pain, postoperative/posttraumatic pain, or shingles experienced reduced pain intensity after multiple high-concentration capsaicin patch applications. The study also showed a significant reduction in opioid use among participants.
Researchers have identified a molecule that reduces hypersensitivity in trials in mice by binding to a protein involved in neuropathic pain. The compound, FEM-1689, has been shown to be an effective painkiller with long-lived effects.
A clinical trial found that trazodone and cognitive behavioral therapy for insomnia were no more effective than placebo in improving insomnia symptoms among long-term dialysis patients. Serious adverse events also occurred more frequently with trazodone use. More trials are needed to investigate additional therapies for this condition.
The PHOTOTHERAPORT project develops luminescent implants that emit light when illuminated, targeting specific regions of the body. The goal is to treat inflammatory pain and neuromodulation therapies for epilepsy using photobiomodulation and photoswitchable drugs.
A recent study found that transient inflammatory pain causes persistent mitochondrial and metabolic disturbances in sensory neurons, leading to failure in pain resolution. Targeting the cellular redox balance prevents and treats chronic inflammatory pain in rodents.
Researchers at Weill Cornell Medicine developed a non-opioid designer molecule to calm hyperactive pain-sensing neurons, showing promising results in preclinical studies. The novel drug effectively reversed neuropathic pain signs without cardiac side effects or sedation.
Researchers from Korea University Medicine have discovered a potential therapeutic target for overcoming cisplatin resistance and neuropathic pain in cervical cancer. By inhibiting TRPV1, they found that resistant tumors became vulnerable to cisplatin, improving the outlook for patients.
Researchers are exploring natural killer cells as a potential treatment for neuropathic pain, which is caused by nerve damage. NK cells may help prune damaged nerve cells, providing relief from chronic pain.
A Cochrane review found that most antidepressants used to manage chronic pain lack sufficient evidence of their effectiveness, with only duloxetine showing reliable pain relief. The review also revealed that harms from many commonly recommended drugs have not been well studied, posing a global public health concern.
Researchers uncover a pathophysiological mechanism that initiates and sustains neuropathic pain in mice, identifying Tiam1 as a potential therapeutic target. Targeting spinal Tiam1 with antisense oligonucleotides alleviates neuropathic pain hypersensitivity, offering promise for treating chronic pain.
Researchers discovered that the gene Tiam1 regulates normal synapse development but also drives structural and functional changes leading to neuropathic pain. Eliminating or blocking Tiam1 activity in animal models prevented or reversed chronic pain, suggesting a potential therapeutic strategy.
The AChemS meeting brings together scientists to understand the fundamental mechanisms of chemosensory systems and their impact on behavior. Key findings include presentations on learning and memory in the chemical senses and physiology of extraoral taste receptors.
A study found that immune checkpoint inhibitors enhance chemotherapy-induced neuropathic pain by blocking interaction between macrophages and neurons via PD1-PDL1 synergy. This discovery could lead to the development of therapeutic alternatives to prevent pain while maintaining anti-neoplastic effects.